Our Medical Advisory Board, chaired by Prof. Andrew Rice, brings together globally recognized clinical scientists and pain specialists, and will enable us to rapidly execute on our shared mission of building a strong pipeline of high-value GPCR modulators derived from our pioneering drug discovery platform.
Andrew S.C. Rice, MD, FRCP, FRCA, FFPMRCA, FFPMCAI (MAB Chairperson), Professor of Pain Research, Imperial College London, UK.
Prof. Rice is active in translational research and clinical practice in the field of neuropathic pain. Much of his current work focuses on the deep profiling and genotyping of cohorts of patients living with neuropathic pain.
Ralf Baron, MD, Head of the Department of Neurological Pain Research and Therapy, Department of Neurology, University of Kiel, Germany.
Dr. Baron’s research focuses on exploring the mechanisms behind the formation of nerve pain, as well as the treatment of neuropathic pain syndromes. He was involved in developing a mechanism-related phenotyping strategy for neuropathic pain patients.
Nanna Brix Finnerup, DrMedSc, MD, Professor and Chair, Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Denmark.
Prof. Finnerup’s research on the pathophysiology and therapy of neuropathic pain includes central and peripheral neuropathic pain conditions, assessment of pain mechanisms and stratified clinical trials.
Robert H. Dworkin, PhD, Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, University of Rochester Medical Center, NY, USA.
Prof. Dworkin is the Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration. His major research interests include the methodologic aspects of analgesic clinical trials and the treatment and prevention of chronic neuropathic and musculoskeletal pain.
Nathaniel Katz, MD, Chief Scientific Officer, Analgesic Solutions, Wayland, MA, USA.
Dr. Katz has completed numerous clinical trials of treatments for pain, both industry-initiated and investigator-initiated, involving pharmaceuticals, non-pharmaceutical analgesics, and devices. He is widely regarded as a global expert in post herpetic neuralgia pain management. He chaired the Advisory Committee to the FDA’s pain division (2000-2004) and is currently the Chief Scientific Officer of WCG Analgesic Solutions.
Mark Versavel, MD, PhD, MBA, President at vZenium LLC, Boston, MA, USA.
Dr. Versavel has over 25 years of clinical development experience in neuropathic pain and in multiple neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials, and in the support of marketed products.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.